Last reviewed · How we verify

Platelet rich fibrin matrix

The New York Eye & Ear Infirmary · Phase 1 active Biologic

Platelet rich fibrin matrix is a Biologic drug developed by The New York Eye & Ear Infirmary. It is currently in Phase 1 development. Also known as: Selphyl.

At a glance

Generic namePlatelet rich fibrin matrix
Also known asSelphyl
SponsorThe New York Eye & Ear Infirmary
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Platelet rich fibrin matrix

What is Platelet rich fibrin matrix?

Platelet rich fibrin matrix is a Biologic drug developed by The New York Eye & Ear Infirmary.

Who makes Platelet rich fibrin matrix?

Platelet rich fibrin matrix is developed by The New York Eye & Ear Infirmary (see full The New York Eye & Ear Infirmary pipeline at /company/the-new-york-eye-ear-infirmary).

Is Platelet rich fibrin matrix also known as anything else?

Platelet rich fibrin matrix is also known as Selphyl.

What development phase is Platelet rich fibrin matrix in?

Platelet rich fibrin matrix is in Phase 1.

Related